Abstract: Biologically active heterodimeric human FSH composed of an alpha subunit and a beta subunit, each subunit being synthesized by a cell having an expression vector containing heterologous DNA encoding the subunit.
Type:
Grant
Filed:
April 24, 1989
Date of Patent:
October 20, 1992
Assignee:
Genzyme Corporation
Inventors:
Vemuri B. Reddy, Nancy Hsiung, Anton K. Beck, Edward G. Berstine
Abstract: Ubiquitin hydrolase is provided having a purity of at least 70% homogeneity based on the weight of the total protein in the composition, which hydrolase hydrolyzes a ubiquitin-polypeptide conjugate at the amide bond linking the ubiquitin and polypeptide, thereby yielding intact polypeptide with an unconjugated, mature N-terminus. Also provided are DNA sequences encoding such ubiquitin hydrolase, as well as expression systems for its recombinant production. Processes are provided for purification of ubiquitin hydrolase from eukaryotes and for its use in recovering any desired polypeptide free from its fusion at its N-terminus with ubiquitin.
Abstract: The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive expression of protein C activity when transformed into an appropriate host cell. The novel expression vectors can be used to produce protein C derivatives, such as non-carboxylated, non-glycosylated, or non-hydroxylated protein C, and to produce protein C precursors, such as nascent or zymogen protein C, and to produce sub-fragments of protein C, such as active or inactive light and heavy chain. The recombinant-produced protein C activity is useful in the treatment and prevention of a variety of vascular disorders.
Type:
Grant
Filed:
July 5, 1988
Date of Patent:
September 29, 1992
Assignee:
Eli Lilly and Company
Inventors:
Nils U. Bang, Robert J. Beckmann, S. Richard Jaskunas, Mei-Huei T. Lai, Sheila P. Little, George L. Long, Robert F. Santerre
Abstract: A method of vaccine or toxoid preparation and immunization against pathogenic disease. An area of the body is colonized with indigenous microorganisms that have been transformed by recombinant DNA technology to express pathogenic antigens. The colonized transformant microorganisms will replicate and elicit an immune response to the pathogenic antigen, thereby protecting the individual from subsequent exposure to the intact pathogen.
Abstract: A microcapsule for oral administration comprising an outer layer membrane which is acid resistant and retains its structure in an alkaline environment, said membrane having dispersed therein at least one enzyme corresponding to an amino acid secreted into the intestinal or derived from a protein or peptide secreted into the intestinal tract. The present invention provides a microcapsule capable of removing specific unwanted amino acids secreted into the intestinal tract.
Type:
Grant
Filed:
June 24, 1991
Date of Patent:
September 15, 1992
Assignee:
The Royal Institution for the Advancement of Learning (McGill University)
Inventors:
Thomas M. S. Chang, Louis Bourget, Colin Lister
Abstract: A method of producing autocrine growth factors from kidney epithelial cells by lowering the extracellular sodium concentration. The invention also concerns new growth factors, a method of producing the new growth factors, and the medium used to produce these new growth factors.
Type:
Grant
Filed:
June 24, 1987
Date of Patent:
August 4, 1992
Assignee:
ARCH Development Corp.
Inventors:
F. Gary Toback, Margaret M. Walsh-Reitz, Stephen L. Gluck
Abstract: This invention relates to deliberately increasing growth hormone in swine during the last 2 weeks of pregnancy through a 3 week lactation. This has the effect of increasing fetal energy storage during late pregnancy which resulted in the newborn piglets having marked enhancement of the ability to maintain plasma concentrations of glucose and free fatty acids when fasted after birth. Likewise, treatment of the sow during lactation results in increased milkfat in the colostrum and an increased milk yield. These effects are important in enhancing survivability of newborn pigs and weight gain prior to weaning.
Type:
Grant
Filed:
April 4, 1989
Date of Patent:
July 28, 1992
Assignee:
Cornell Research Foundation, Inc.
Inventors:
R. Dean Boyd, Dale E. Bauman, Walter R. Butler
Abstract: A composition for thrombolytic therapy includes a tissue-type plasminogen activator (t-PA) and a low affinity heparin fraction. The composition is administered intravenously to allow the t-PA to dissolve blood clots while the low affinity heparin fraction prevents reocculsion without the harmful side effects observed for unfractionated heparin, such as, stimulation of and interference with t-PA activity in the circulatory system, as well as, interference with fibrinolytic activity which can cause hemorrhaging in the mammalian circulatory system.
Type:
Grant
Filed:
November 4, 1988
Date of Patent:
July 14, 1992
Assignee:
The Research Foundation of State University of New York
Abstract: A stable aqueous thrombin solution containing thrombin and a sugar and an amino acid as a stabilizer is disclosed. According to the present invention, there is provided a stable aqueous thrombin solution.
Abstract: A method of percutaneously administering a physiologically active agent which comprises applying to the skin of a mammal a physiologically active agent in a carrier system which comprises at least one adjuvant, at least one solvent and at least one diol and/or triol moderator. The adjuvant can be selected from aliphatic hydrocarbons, halogen substituted aliphatic hydrocarbons, alcohol esters of aliphatic carboxylic acids, mono- or di-ethers, ketones, higher monoalcohols or mixtures thereof. The solvent can be selected from thioglycerols, lactic acid and esters thereof, cyclic ureas, compounds represented by the general formula R.sub.1 R.sub.2 NCONR.sub.3 R.sub.4, pyrrolidone-type compounds, amides, lactones or mixtures thereof.
Type:
Grant
Filed:
September 4, 1990
Date of Patent:
July 7, 1992
Assignee:
Nitto Denko Corporation
Inventors:
Kenichiro Saito, Jorge Heller, Wilfred A. Skinner
Abstract: There is provided a pharmaceutical composition comprising as component A a plasminogen activator and as component B hirudin together with a pharmaceutically acceptable carrier. The pharmaceutical composition can be used for the prophylaxis and therapy of thrombosis or diseases caused by thrombosis.
Type:
Grant
Filed:
September 18, 1989
Date of Patent:
June 30, 1992
Assignees:
Ciba-Geigy Corporation, UCP Gen-Pharma AG
Abstract: The present invention provides a method for improving stick yield of a celery line which comprises culturing an explant on a first medium containing at least one auxin to produce callus, culturing the callus on a second medium without growth regulators to produce embryos, growing embryos unit mature plants are obtained and recovering from the mature plants variants exhibiting a stick yield of at least about 25% over stick yield of the parent line. Also provided are novel celery plants, having improved stick yield.
Abstract: An anticoagulant composition containing an effective amount of factor Xa having the active serine site inactivated that functions rapidly and effectively in vivo to suppress coagulation. In a preferred embodiment, Factor Xa, a serine esterase that forms a complex with Factor Va, Ca++, and phospholipid to catalyze prothrombin activation, is first inactivated with an active site inhibitor, such as dansyl-glu- gly-arg-chloromethyl ketone, to form inactivated factor Xa. In another embodiment, Factor Xa is expressed from a gene sequence wherein the portion encoding the active serine region is modified. The inactivated protein retains the ability to bind to endogenous factor Va in vivo, and has a half-life of approximately ten hours. Administration of inactive factor Xa to the blood of a patient results in the formation of inactive factor Xa-Va complexes in vivo, thereby inhibiting coagulation.
Type:
Grant
Filed:
June 14, 1989
Date of Patent:
June 9, 1992
Assignee:
Oklahoma Medical Research Foundation
Inventors:
Charles T. Esmon, Fletcher B. Taylor, Jr.
Abstract: The invention provides a composition and method for treating benign prostatic hypertropy in mammals so as to cause the dissolution and regression of hypertrophied prostatic tissue and thereby provide relief from the obstructive symptoms associated with the disease. The present composition preferably comprises a sterile pyrogen-free solution of the hydrolytic enzymes collagenase and hyaluronidase, a nonionic surfactant, and an antibiotic; all provided, in a pharmaceutically acceptable, buffered, isotonic, aqueous carrier. The present method preferably comprises the direct intraprostatic injection of a safe and therapeutically effective dose of the composition via the transurethral route of administration.
Abstract: A pharmaceutical composition containing serum thymic factor (FTS) and a method for using FTS containing compositions for treating a variety of immunodeficiencies and autoimmune diseases including multiple sclerosis, Guillain-Barre syndrome, inflammatory neuropathy, polyneuritis and other immunodemyelinating diseases.
Abstract: A method of determining the presence of epithelial lesions is provided wherein a sample of a body fluid taken from an epithelial region suspected to have said lesions is tested for the presence of a proteolytic activity. The lesion is then treated by applying a therapeutically effective amount of a proteinase inhibitor in the form of a physiologically acceptable preparation, a pharmaceutical preparation of aprotinin being particularly preferred.
Abstract: Purified BMP-1 proteins and processes for producing them are disclosed. They may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
July 31, 1990
Date of Patent:
April 28, 1992
Assignee:
Genetics Institute, Inc.
Inventors:
Elizabeth A. Wang, John M. Wozney, Vicki Rosen
Abstract: This invention pertains to the identification and isolation of a novel fungus which can be used for growth stimulation in plants. A method of promoting plant growth using the novel fungus is provided.
Type:
Grant
Filed:
November 1, 1988
Date of Patent:
April 21, 1992
Assignee:
University of Florida
Inventors:
Robert T. McMillan, Jr., Komaratchi R. Narayanan